B. Riley initiated coverage of Cytokinetics with a Buy rating and $66 price target. The analyst views the company’s most advanced cardiology therapeutics candidate, aficamten, as “significantly de-risked” in the three ongoing Phase III studies to become the cardiac myosin inhibitor therapy of choice for hypertrophic cardiomyopathy patients. The firm believes aficamten differentiation remains underappreciated
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK: